ÂÜÀòÂÒÂ×

With her doctorate degree in Chemistry, Dr. Humblet spent her early day’s career in academia where she developed and applied computer-assisted molecular modeling techniques while building the foundation and blueprint for the software Sybyl, later commercialized by Tripos Inc. At the time, her research focused in the Pain, Neurosciences and Cardiovascular areas to elucidate structure-activity patterns for fentanyl, gabapentin, serotonin inhibitors among others. She transitioned to the Pharmaceutical Industry, initially as an individual contributor, and grew into an exceptional scientific and technical leader in preclinical discovery and enabling technologies. Her journey began at Parke-Davis in Ann Arbor, Michigan. It proceeded with appointments as a Director of Informatics at Abbott and a Senior Director of Computational Chemistry & Cheminformatics at Wyeth. Most recently, she led cheminformatics initiatives to transform drug discovery through artificial intelligence and machine learning techniques at Eli Lilly. Dr. Humblet has been published in more than 115 publications. She obtained her PhD from the University of Namur, Belgium